Atlas/Track record
G12D: 31 trials since 2019. 31 reached Phase 1, 20 Phase 2, 8 Phase 3, 0 approved.
25 ongoing, 0 positive, 0 negative, 0 finished without posted results, 6 stopped early. Outcomes and badges come from the knowledge API as of 2026-11-02.
Where trials stop
Not in the data yet: why trials stopped. 6 of the 6 stopped trials have no classified reason yet (ClinicalTrials.gov “why stopped”, knowledge gap K1). They are counted as “reason not known yet”, never guessed.
Every trial, in order
| Start | Trial | Phase | Outcome | Status | Why stopped | |
|---|---|---|---|---|---|---|
| 2019-05 | NCT03745326↗ Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mut… | Phase 1 / Phase 2 | Stopped early | Terminated | not known yet | |
| 2021-01 | NCT03608631↗ iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Phase 1 / Phase 2 | Ongoing | Recruiting | — | |
| 2023-03 | NCT05737706↗ Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | Stopped early | Terminated | not known yet | |
| 2023-09 | NCT06040541↗ |